The DOI matches its Crossref record.
The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate Carcinoma
Open accessAbstract
For prostate cancer, a correlation exists between overexpression of the epidermal growth factor receptor (EGFR) and poor clinical prognosis. In addition, late-stage metastatic disease is characterized by a change from a paracrine to an autocrine mode of expression for TGF-alpha, the ligand for the EGFR. These observations suggest that activation of the EGFR may be important for the growth of prostatic carcinoma in situ, and blockade of the receptor-ligand interaction may offer a means of therapeutic intervention for this disease. We describe the biologic effects of a chimeric anti-EGFR monoclonal antibody, C225, on several human prostate tumor cell lines in culture and the tumor inhibitory properties of the antibody for the treatment of human prostate carcinoma xenografts in nude mice. In vitro analysis of the EGFR from androgen-responsive and independent prostatic carcinoma cell lines revealed that C225 blocked EGF-induced receptor activation and induced internalization of the receptor. In vivo, a treatment regimen of C225 alone or antibody plus doxorubicin significantly inhibited tumor progression of well-established DU145 and PC-3 xenografts in nude mice. These results suggest that C225 may have utility for the treatment of human prostate carcinoma in a clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 827
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Dittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Raju, U., Milas, L., Chen, D. J., Kehlbach, R., & Rodemann, H. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506591200 · Cited by 529
United States Food and Drug Administration Drug Approval Summary
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., McGuinn, W. D., Morse, D., Abraham, S., Rahman, A., Liang, C., Lostritto, R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0564 · Cited by 503
Metadata
- Authors
- Prewett, M., Scher, H. I., Rockwell, P., Rockwell, R. F., Giorgio, N. A., Mendelsohn, J., & Goldstein, N. I.
- Venue
- Journal of Immunotherapy
- Published
- 1996-11
- Volume
- 19
- Issue
- 6
- Pages
- 419-427
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W1983104536
- Cited by
- 244
- References
- 0
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate Carcinoma. https://app.cochat.ai/papers/10.1097/00002371-199611000-00006
- The paper
- Prewett, M., Scher, H. I., Rockwell, P., Rockwell, R. F., Giorgio, N. A., Mendelsohn, J., & Goldstein, N. I. (1996). The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate Carcinoma. Journal of Immunotherapy. https://doi.org/10.1097/00002371-199611000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.